The optimized synthesis of a range of cyclooctadiene-stabilized Pt complexes that contained different perfluoro-alkane chains, [Pt(cod)Me(Cn F2n+1 )], is presented. These metal-organic compounds were employed in the so-called supercritical fluid reactive deposition (SFRD) in CO2 under reductive conditions to generate metallic nanoparticles on aluminum oxide as a porous support. Thus, Al2 O3 -supported Pt nanoparticles with a narrow particle-size distribution were obtained. At a reduction pressure of 15.5 MPa and a temperature of 353 K, particle diameters of d50 =2.3-2.8 nm were generated. Decreasing the pressure during the reduction reaction led to slightly larger particles whilst decreasing the amount of organometallic precursor in CO2 yielded a decrease in the particle size from x50 =3.2 nm to 2.6 nm and a particle-size distribution of 2.2 nm. Furthermore, substitution of the CH3 end group by the Cn F2n+1 end groups led to a significant drop in Pt loading of about 50 %. Within the series of perfluorinated end groups that were considered, the Pt complex that contained a branched perfluoro-isopropyl group showed the most-interesting results when compared to the control precursor, [Pt(cod)Me2 ] (1).
This contribution reports on the impact of the rapid expansion of supercritical solutions (RESS) on poly(vinylidene fluoride) (PVDF) properties in terms of particle size, molar mass distribution, crystal phase and finally piezoelectric behavior. Based on the usage of a phase PVDF powders, submicron particles were obtained involving crystal phase conversion to the b form. Moreover, state of the art piezoresponse force microscopy analysis verifies the formation of piezoelectric PVDF particles via RESS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.